Filing Details

Accession Number:
0001209191-21-009637
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-11 16:07:43
Reporting Period:
2021-02-09
Accepted Time:
2021-02-11 16:07:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1725018 Gianfranco Nazzi C/O Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva L3 4951033
Evp, International Markets No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-02-09 11,941 $0.00 31,785 No 4 M Direct
Ordinary Shares Acquisiton 2021-02-09 50,260 $0.00 82,045 No 4 A Direct
Ordinary Shares Disposition 2021-02-09 4,155 $12.72 77,890 No 4 S Direct
Ordinary Shares Disposition 2021-02-09 17,480 $12.72 60,410 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2021-02-09 11,941 $0.00 11,941 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,941 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  3. Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.
  4. Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share.
  5. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  6. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  8. Restricted share units were granted on February 9, 2018, with 11,941 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.